Revive Therapeutics Partners With University of Wisconsin-Madison For Psilocybin-Based Research

Revive Therapeutics (CSE: RVV) announced this morning that it has entered into a sponsored research partnership agreement with that of the University of Wisconsin-Madison. The partnership arrangement will see the University of Wisconsin-Madison work with the company to evaluate novel formulations and drug delivery tech focused on psilocybin-based pharmaceuticals.

The program will be conducted at the Reed Research Group, led by Dr Jess D Reed who is the Professor of Animal Sciences at the university. The research agreement with the University and Revive will see the evaluation of psilocybin-based formulations and the patented Tannin-Chitosan composite drug delivery tech for psilocybin. Revive has an exclusive licenses with the Wisconsin Alumni Research Foundation for this technology.

The tech behind the drug delivery method is focused on delivering both synthetic and natural extracts of psilocybin in a number of potential mediums. Potential methods include topical gels, creams or ointments, oral dosages, foams, and oral or transdermal patches. The method is a natural, non-toxic, biodegradable and biocompatible composite. The tech has rapid onset capabilities and may allow for the combining of multiple extracts from mushrooms in a single formulation.

"We are excited to partner with the University of Wisconsin-Madison and leverage our intellectual property of psilocybin-based formulations and our drug delivery technology to advance novel psilocybin-based pharmaceuticals for certain medical needs. We have established a sound foundation to allow us to efficiently develop unique psychedelic-based pharmaceuticals with the objective to investigate our drug products in clinical trials in the U.S."  - Michael Frank, CEO

In addition to the tech having a composite that is derived from a plant group having a number of antibacterial and antifungal properties, it offers licensed pharma firms new product opportunities for various medical disorders.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Revive Therapeutics last traded at $0.14 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

  1. This doesn’t look any more real or any more fake than the rest of the shroom deals. Not sure how anyone can assess the commercial viability of these.

Video Articles

Seabridge Loses KSM’s Substantially Started Status

This Gold Giant Got Crushed… Now It’s the Cheapest Major | Kinross Gold’s Q3 Earnings

Why I’m Still Bullish on Gold Below $3,900 | Wes Hanson – Thunder Gold

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Orogen Sees Flat Net Income In Q4 2025 Despite Record Revenue

Orogen Royalties (TSXV: OGN) posted its strongest year on record in 2025, with total revenue...

Tuesday, March 24, 2026, 10:07:00 AM

Will Oil Bottom Soon? Prices Continue To Hit Lows

Oil futures are on track to reach the lowest prices on record since the start...

Tuesday, November 29, 2022, 12:41:00 PM

Bitcoin Jumps After Tesla Begins Accepting Crypto as Payment for Cars

The price of bitcoin rose by nearly 5% to above $55,000 on Wednesday, after Elon...

Saturday, March 27, 2021, 04:47:00 PM

BMO Explores Sale of US Branches Worth $6 Billion in Deposits

Bank of Montreal (TSX: BMO) is exploring the potential sale of some US branches holding...

Thursday, September 25, 2025, 07:41:00 AM

Venerable Ventures Plans To Acquire Kapoose Creek Wellness In An All-Share Transaction

Venerable Ventures Ltd. (TSXV: VLV) announced on Wednesday night its letter of intent to acquire...

Thursday, September 9, 2021, 11:26:00 AM